Compare IDEXX Laboratories, Inc. (IDXX) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs BlackRock TCP Capital Corp — how do they compare? IDEXX Laboratories, Inc. trades at $546.1 (market cap $43.58B), while BlackRock TCP Capital Corp trades at $3.2 (market cap $271.84M). The key difference: IDEXX Laboratories, Inc. is far larger — about 160.3× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 25.93% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | TCPC | |
|---|---|---|
Market Cap | $43.58B | $271.84M |
Sector | Health | Financials |
52-Week High | $766.68 | $7.64 |
52-Week Low | $526.44 | $3.14 |
Enterprise Value | $44.48B | — |
Dividend Yield | — | 25.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories trades at $552.46, down 2.64% today, with neutral technical signals but strong fundamental performance. The company maintains robust profitability with 24.63% net margins and has beaten earnings expectations for three consecutive quarters. Recent news highlights AI integration in medical devices and upcoming Q2 2026 results on August 4, 2026. The stock shows consistent revenue growth from $3.4B in 2022 to $4.3B in 2025.
Outlook remains positive given earnings momentum and analyst consensus, though elevated valuation ratios (P/E 41.49) pose risks. Key catalysts include Q2 earnings release and continued AI adoption in veterinary diagnostics. Primary risks involve competitive pressures and market volatility affecting premium valuations.
TCPC trades at $3.21, down 3.02% today, with a bearish technical signal from moving averages. The company reported negative revenue and net losses in 2025, though it beat Q1 2026 EPS estimates. A dividend of $0.17 per share is scheduled for June 30, 2026. Analyst consensus is mixed, with 31% buy ratings but 54% hold, reflecting caution amid financial challenges and an ongoing legal investigation into fiduciary duties.
The outlook remains cautious due to persistent negative earnings and revenue trends, with profitability metrics like ROE at -18.74% indicating weak shareholder returns. Risks include the shareholder lawsuit and competitive pressures in the BDC sector. Near-term focus is on the Q2 2026 earnings report due August 6, 2026, which could influence sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
